Enfortumab Vedotin as Third-Line Treatment Improves Overall Survival for Patients with Advanced Urothelial Carcinoma in the EV-301 Trial

Enfortumab Vedotin as Third-Line Treatment Improves Overall Survival for Patients with Advanced Urothelial Carcinoma...

Efortumab vedotin prolonged OS in patients who had previously received chemotherapy and checkpoint inhibitors for advanced urothelial carcinoma.

Curated Journal reading List

Advertisement
Advertisement

Expert Interviews